1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2022, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 5, 3, 15, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase 0, Preclinical and Discovery stages comprises 2, 1, 2 and 2 molecules, respectively.
Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Neisseria meningitidis Infections - Overview
- Neisseria meningitidis Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Neisseria meningitidis Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
- Neisseria meningitidis Infections - Drug Profiles
- Neisseria meningitidis Infections - Dormant Projects
- Neisseria meningitidis Infections - Discontinued Products
- Neisseria meningitidis Infections - Product Development Milestones
- Featured News & Press Releases
- Jan 08, 2022: CanSinoBIO announces approval for its MCV4 product Menhycia in China
- Sep 27, 2021: New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline including MenQuadfi and commitment to advancing public health protection
- Jul 12, 2021: Sanofi’s meningococcal disease jab meets all endpoints in Phase III trial
- Jan 15, 2021: Microsuper-biological tetravalent meningococcal conjugate vaccine formally submitted for IND application
- Nov 23, 2020: European Commission approves MenQuadfi, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
- Sep 17, 2020: Sanofi receives CHMP positive opinion for MenQuadfi intended for prophylaxis against invasive meningococcal disease
- Jun 22, 2020: Pfizer announces start of Phase 3 Clinical Trial of MenABCWY
- May 29, 2020: The European Medicines Agency has finalised its assessment of an application to extend the use of Trumenba for the prevention of invasive meningococcal disease
- Aug 29, 2019: $440 million funding boost for vital health and medical research for all stages of life
- Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis
- Jun 27, 2018: European approval for lower dose of GSk's Meningitis vaccine
- Jun 18, 2018: New way to determine protection of Men B vaccine against different strains
- Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
- Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada
- Feb 07, 2018: GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Neisseria meningitidis Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Neisseria meningitidis Infections - Pipeline by AIM Vaccine Co Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Alopexx Inc, 2022
- Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Biological E Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, 2022
- Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, 2022
- Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Eubiologics Co Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by GSK plc, 2022
- Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Intravacc BV, 2022
- Neisseria meningitidis Infections - Pipeline by Inventprise LLC, 2022
- Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, 2022
- Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Omvax Inc, 2022
- Neisseria meningitidis Infections - Pipeline by Pfizer Inc, 2022
- Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, 2022
- Neisseria meningitidis Infections - Pipeline by Sanofi, 2022
- Neisseria meningitidis Infections - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022
- Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, 2022
- Neisseria meningitidis Infections - Dormant Projects, 2022
- Neisseria meningitidis Infections - Dormant Projects, 2022 (Contd..2)
- Neisseria meningitidis Infections - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Neisseria meningitidis Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AIM Vaccine Co Ltd
- Alopexx Inc
- Beijing Minhai Biotechnology Co Ltd
- Biological E Ltd
- Bioworld Technologies Sdn Bhd
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- Eubiologics Co Ltd
- GSK plc
- Hilleman Laboratories Pvt Ltd
- ImmunoBiology Ltd
- Intravacc BV
- Inventprise LLC
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co Ltd
- Neoculi Pty Ltd
- Novo Medi Sciences Pvt Ltd
- Omvax Inc
- Pfizer Inc
- ReAlta Life Sciences Inc
- Sanofi
- Suzhou Weichao Biotechnology Co Ltd
- Wellstat Vaccines LLC
